Melanocortin type 4 receptor–mediated inhibition of A-type K⁺ current enhances sensory neuronal excitability and mechanical pain sensitivity in rats

Yuan Zhang 1,2,6, Dongsheng Jiang 2,4,6, Hua Li 3, Yufang Sun 2, Xinghong Jiang 2, Shan Gong 2, Zhiyuan Qian 1,*, Jin Tao 2,5,*
1 Department of Geriatrics, the Second Affiliated Hospital of Soochow University, Suzhou 215004, P.R. China; 2 Department of Physiology and Neurobiology & Centre for Ion Channelopathy, Medical College of Soochow University, Suzhou 215123, P.R. China; 3 National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai 201203, P.R. China; 4 Comprehensive Pneumology Center, Helmholtz Zentrum München, Munich 81377, Germany; 5 Jiangsu Key Laboratory of Neuropsychiatric Diseases, Soochow University, Suzhou 215123, P.R. China
* These authors contribute to this work equally.
Running title: MC4R inhibits A-type K⁺ currents

To whom correspondence should be addressed: Dr. Zhiyuan Qian, Department of Geriatrics, the Second Affiliated Hospital of Soochow University, 1055 San-Xiang Road, Suzhou 215004, P.R. China. E-mail: zhiyuanqian@suda.edu.cn
Dr. Jin Tao, Department of Physiology and Neurobiology & Centre for Ion Channelopathy, Medical College of Soochow University, 199 Ren-Ai Road, Suzhou 215123, P.R. China. E-mail: taoj@suda.edu.cn

Keywords: alpha-melanocyte stimulating hormone; A-type K⁺ current; trigeminal ganglion neurons; neuronal excitability; pain perception; nociception, melanocortin type 4 receptor (MC4R); G protein–coupled receptor; action potential; cell signaling

Abstract
Alpha-melanocyte–stimulating hormone (α-MSH) has been shown to be involved in nociception, but the underlying molecular mechanisms remain largely unknown. In this study, we report that α-MSH suppresses the transient outward A-type K⁺ current (I_A) in trigeminal ganglion (TG) neurons and thereby modulates neuronal excitability and peripheral pain sensitivity in rats. Exposing small-diameter TG neurons to α-MSH concentration-dependently decreased I_A. This α-MSH–induced I_A decrease was depended on the melanocortin type 4 receptor (MC4R) and associated with a hyperpolarizing shift in the voltage dependence of A-type K⁺ channel inactivation. Chemical inhibition of phosphatidylinositol 3-kinase (PI3K) with wortmannin or of class I PI3Ks with the selective inhibitor CH5132799 prevented the MC4R–mediated I_A response. Blocking G_i/o-protein signaling with pertussis toxin or by dialysis of TG neurons with the Gβγ-blocking synthetic peptide QEHA abolished the α-MSH–mediated decrease in I_A. Further, α-MSH increased the expression levels of phospho-p38 mitogen-activated protein kinase (MAPK), and pharmacological or genetic inhibition of p38 alpha (p38α) abrogated the α-MSH–induced I_A response. Additionally, α-MSH significantly increased the action potential firing rate of TG neurons and increased the sensitivity of rats to mechanical stimuli applied to the buccal pad area, and both effects were abrogated by I_A blockade. Taken together, our findings suggest that...
α-MSH suppresses $I_A$ by activating MC4R, which is coupled sequentially to the $G_{i/o}$ complex of the $G_{i/o}$ protein and downstream class I PI3K–dependent p38α signaling, thereby increasing TG neuronal excitability and mechanical pain sensitivity in rats.

Introduction
The alpha-melanocyte stimulating hormone (α-MSH) is primarily a pigmentary hormone derived from proopiomelanocortin (POMC), a common precursor protein of all melanocortin peptides, which predominantly expresses in the pituitary gland (1). Five G-protein coupled melanocortin receptors, named MC1R - MC5R, have been characterized as the endogenous receptors of α-MSH (2). These receptors differ in their tissue distribution and in their ability to recognize various melanocortins. Consistent with the distribution of MCRs in the nervous system (mainly MC3R and MC4R) and peripheral organs (3), α-MSH exerts a large array of behavioral effects and regulates a variety of physiological functions, including blood pressure regulation, grooming, immunity, and body weight homeostasis (4-5). Additionally, in vivo studies have revealed that α-MSH, as well as the melanocortin receptor agonist melanotan II, causes hyperalgesia in various pain models (6-8). Further support to this hypothesis came from the observation that antagonism of the MC3R and MC4R can effectively alleviate chronic constriction injury (CCI)-induced allodynia (9-10). Nevertheless, the contributing mechanisms underlying α-MSH hyperalgesic actions are not well understood.

Alterations in the excitability of nociceptive sensory neurons can directly affect allostynia and hyperalgesia, the two common symptoms of pain (11). Voltage-gated ion channels including $K^+$ channels (Kv) are pivotal determinants of membrane excitability in peripheral nociceptive neurons (12) and are classified into two major categories: A-type and delayed rectifier channels, which respectively mediate currents of $I_A$ and $I_{DR}$ (13-14). $I_A$ is defined by their sensitivity to 4-aminopyridine, and their rapidly activating and quick inactivating characteristics (15). These channels play critical roles in determining the intrinsic membrane properties and the excitability of nociceptive neurons (12-13), and they have been widely implicated in pain plasticity (15). For instance, peripheral nerve injury was shown to induce the down-regulation of $I_A$, resulting in increased excitability of sensory neurons, which may increase the responsiveness to nociceptive stimulation (16). In addition, genetic and functional analyses have firmly established an important role of A-type channels in amplifying nociceptive signals in the periphery and in contributing to central sensitization in the spinal dorsal horn (15,17-18). Manipulation of A-type channels, therefore, is expected to modulate intrinsic neuronal excitability and subsequent nociceptive transmission, which is considered useful for pain therapy.

In the present study, we determined the role of α-MSH in regulating $I_A$ and elucidated the detailed mechanisms underlying the actions of α-MSH in small-diameter (< 30 μm) TG neurons. Our findings demonstrated that α-MSH decreased $I_A$ via a $G_{i/o}$-dependent class I PI3K and the downstream p38α signaling pathway. This response occurred through the MC4R activation and contributed to the neuronal hyperexcitability of TG neurons and pain hypersensitivity in rats.

Results
α-MSH selectively decreases $I_A$ in small-sized TG neurons

In vitro study of nociceptive and other forms of sensory processing usually examine different subtypes of peripheral sensory neurons (19-23). In this study, we sorted adult rat TG neurons into small-sized (< 30 μm in soma diameter) and medium-sized (30 - 45 μm in soma diameter) groups, and limited the whole-cell recording to the small ones, as these neurons played pivotal roles in the nociceptive processing (20,24). Kv currents in the small-sized nociceptive neurons are functionally characterized into two main types including a transient outward, A-type K$^+$ current ($I_A$) and a delayed rectifier K$^+$ current ($I_{DR}$) (13,25).

Therefore, we first separated the two kinetically different whole-cell currents in our patch clamp recordings. A whole-cell outward K$^+$ current was elicited by a command potential of +40 mV from a holding potential of -80 mV in TG neurons (Fig. 1A). The typical current profile observed in these neurons exhibited a component characteristic for fast inactivating and a following sustained portion. After inactivating the transient outward K$^+$ currents by a 150-ms-long prepulse, only the $I_{DR}$ was left. Further off-line subtraction of $I_{DR}$ from the total outward current yielded $I_A$ (Fig. 1A). The application of 5 mM 4-aminopyridine (4-AP) to TG neurons dramatically inhibited this $I_A$ (decrease of 81.9 ± 5.1 % at +40 mV, $n = 9$; Fig. 1B), indicating the effective separation of $I_A$. Bath application of α-MSH (0.1 μM) significantly reduced the peak current amplitude of $I_A$ (Fig. 1C and D). Further investigation showed that the α-MSH induced $I_A$ suppression was concentration-dependent and had a median effective concentration (EC$_{50}$) of 36.9 nM (Fig. 1E).

We then investigated whether the biophysical properties of A-type channels was also affected by α-MSH. The current-voltage relationships (I/V curves) indicated that at each test potential above -20 mV, 0.1 μM α-MSH significantly reduced the peak current amplitude of $I_A$ (Figs. 1F and G), and at +40 mV, the peak current density of $I_A$ decreased from 134.7 ± 21.7 to 78.3 ± 15.8 pA/pF ($n = 8$; Fig. 1G). Next, we analyzed the voltage dependence of activation and inactivation potentials following the α-MSH application. While the potential of voltage-dependent activation did not change significantly ($V_{half}$ from 8.9 ± 2.4 mV to 9.7 ± 3.3 mV; $n = 12$; Figs. 1H and J), application of 0.1 μM α-MSH to TG neurons significantly shift the inactivation curve toward hyperpolarizing direction by ~10.7 mV ($V_{half}$ from -52.6 ± 1.9 mV to -63.3 ± 1.4 mV; $n = 12$; Figs. 1I and J). These results reveal that the increased proportion of A-type channels in the steady-state inactivation might contribute to the α-MSH-induced $I_A$ decrease.

The MC4R mediates the α-MSH-induced $I_A$ decrease

Five types of melanocortin receptors in the mammalian genome has been identified as the endogenous receptors for α-MSH, among which only MC3R and MC4R prominently expressed in the spinal cord and dorsal root ganglia (DRG) (3,7,26-27). We determined the participation of these two receptors in α-MSH-induced $I_A$ decrease by first examining the expression profile of MC3R and MC4R. Reverse transcription (RT)-PCR analysis...
demonstrated that only the MC4R transcripts (the predicted size is 923 bp), but not the MC3R (the predicted size is 307 bp), were detected in rat TG tissues (Fig. 2A). The MC4R protein expression in TGs was confirmed by western blotting (Fig. 2B). Next, we analyzed the subcellular localization of MC4R protein by immunofluorescent staining. In rat TG sections, 32.5 ± 6.3% of MC4R-positive neurons were co-stained with IB4, and 43.9 ± 5.2% of MC4R-positive neurons exhibited immunoreactivity for CGRP (Figs. 2C and D). In contrast, only 7.5 ± 1.7% of MC4R-positive neurons was positive for neurofilament 200 (NF200), a specific marker for neurons with myelinated fibers (Figs. 2C and D). The expression pattern of MC4R suggests that it might be involved in the α-MSH-mediated $I_A$ response in small-sized TG neurons. Indeed, the pretreatment of cells with 0.5 µM HS024, a selective MC4R antagonist, completely abolished the 0.1 µM α-MSH-mediated decrease in $I_A$ (decrease of 2.1 ± 0.9 %, n = 9; Figs. 2E and F), while application of HS024 (0.5 µM) alone has no effects on $I_A$ (Figs. 2E and F). Next, we investigated whether selective activation of MC4R mimics the inhibitory effect of α-MSH. Indeed, bath application of 0.2 µM Ro 27-3225, a specific MC4R agonist, dramatically decreased the peak amplitude of $I_A$ (27.7 ± 1.9 %, n = 6; Figs. 2G and H), further supporting the involvement of MC4R in α-MSH-induced $I_A$ decrease.

**The MC4R mediates $I_A$ decrease via the Gβγ-dependent PI3K signaling**

The signaling of MC4R activation in a variety of primary cells and tissues are known to act via heterotrimeric Gs-proteins (28). Pre-incubating TG neurons with 0.5 µg/ml cholera toxin (CTx), which was effectively inactivate Gαs (24,29), did not affect the α-MSH-induced $I_A$ response (decrease of 29.1 ± 3.7 %, n = 10; Figs. 3A and C). Contrastingly, inhibition of Gαs by pretreatment with 0.2 µg/ml pertussis toxin (PTx) for 16 h abolished the inhibitory effect of α-MSH on $I_A$ (decrease of 1.2 ± 3.9 %, n = 8; Figs. 3B and C). Dialysis of small-sized TG neurons with 10 µM QEHA, a synthetic peptide that competitively binds Gβγ and blocks the Gβγ-mediated signaling (30), prevented the α-MSH-induced response in $I_A$ (decrease of 2.1 ± 1.8 %, n = 8; Figs. 3D), while intracellular application of SKEE (10 µM), the scrambled peptide of QEHA, did not elicit such effects (decrease of 34.1 ± 4.6 %, n = 11; Fig. 3D). These results suggest that the Gβγ complex of Gi/o-protein participate in the MC4R-induced $I_A$ decrease. Previous studies showed that protein kinase A (PKA) was downstream of Gβγ activation (31); however, dialyzing small TG neurons with 1 µM PKI 6-22 , a synthetic peptide inhibitor of PKA, did not alter the ability of α-MSH to decrease $I_A$ (decrease of 31.2 ± 3.9 %, n = 9; Figs. 3D). The PKI 6-22 at 1 µM was effective in this assay since the intracellular administration of PKI 6-22 resulted in a nearly complete blockade of 20 µM forskolin-induced $I_A$ response (decrease of 1.5 ± 3.1 %, n = 7; Fig. 3E). PI3K activation has been shown to modulate $I_A$ and act as a downstream effector of Gβγ activation (32). Either application of 0.1 µM α-MSH or the selective MC4R agonist Ro 27-3225 at 0.2 µM significantly enhanced the PI3K activity, and the pretreatment of TG neurons with the selective MC4R antagonist HS024 at 0.5 µM completely abolished these effects (Fig. 3F). Further, pretreating TG neurons with 0.5 µM wortmannin, a PI3K inhibitor (decrease of 3.1 ± 2.7 %, n = 8; Fig. 3G), or 1 µM CH5132799, a selective inhibitor of
class I PI3Ks (decrease of 1.1 ± 3.9 %, n = 7; Fig. 3G), completely abolished the α-MSH-mediated decrease in $I_A$, indicating the requirement of class I PI3K in the MC4R-mediated $I_A$ response.

**The α-MSH-induced $I_A$ decrease requires p38 MAPK**

Akt is a common and major downstream target of PI3K. Therefore, we examined whether the α-MSH action in TG neurons was through the Akt activation. Although the phosphorylated Akt (p-Akt) level was significantly increased following the α-MSH treatment (Fig. 4A), the inhibition of Akt activity by 10 μM Akt inhibitor III showed no influence on 0.1 μM α-MSH induced $I_A$ decrease (decrease of 31.9 ± 7.6 %, n = 11; Fig. 4B). This finding suggests that the α-MSH-induced $I_A$ response is independent of Akt. It has been shown that mitogen-activated protein kinase (MAPK) cascades play pivotal roles in pain sensation (33), and the MAPK family molecules are involved in the regulation of $I_A$ (34). Therefore, subsequently we investigated in TG neurons whether MAPK participated in the MC4R-mediated decrease in $I_A$. Immunoblot analysis indicated that exposure of TG cells to 0.1 μM α-MSH markedly increased phosphorylated p38 (p-p38), while the total p38 (t-p38), as well as p-JNK and p-ERK expression levels, remained unaffected (Fig. 4C). Pre-incubation of TG cells with the PI3K antagonist wortmannin at 0.5 μM eliminated the α-MSH-induced p38 activation (Fig. 4D), indicating the involvement of PI3K-dependent p38 MAPK activation. Furthermore, the pretreatment of TG neurons with the p38 MAPK inhibitor SB203580 at 10 μM abrogated the α-MSH-induced decrease in $I_A$ (decrease of 2.9 ± 2.1 %, n = 9; Figs. 4E and G). Contrastingly, the negative control compound SB202474, which is structurally related to SB203580, but does not inhibit p38 MAPK activity, elicited no such effects at the same concentration (decrease of 30.9 ± 4.9 %, n = 7; Figs. 4F and G). Thus, the Akt-independent p38 MAPK activation is required for the α-MSH–induced $I_A$ decrease in TG neurons.

**p38α mediates the α-MSH-induced $I_A$ response**

In the nervous system, such as in rat spinal cord, two major isoforms of p38 including p38α and p38β exist (Fig. 5A). We further dissected the exact p38 isoform involved in the α-MSH-induced $I_A$ decrease in rat TG neurons. Western blot analysis revealed that only p38α but not p38β was endogenously expressed in adult rat TGs (Fig. 5A). Pretreating TG neurons with 50 nM JX-401, a potent inhibitor specific to p38α isoform, completely abolished the 0.1 μM α-MSH-mediated decrease in $I_A$ (decrease 2.9 ± 3.5 %, n = 9; Fig. 5B). To further confirm this specific p38α-mediated signaling pathway, we utilized an adenoviral-based shRNA approach to knockdown p38α in TG cells. In contrast to the substantial expression of p38α in the cells transduced with negative control shRNA (NC-shRNA), the protein expression level of p38α was markedly reduced in TG cells transduced with the p38α-specific shRNA (p38α-shRNA, Fig. 5C). Knockdown of p38α in TG neurons led to the attenuation of the α-MSH-mediated decrease in $I_A$ (decrease 2.3 ± 2.1 %, n = 17; Fig. 5D), indicating that p38α is specifically involved in the α-MSH-induced $I_A$ decrease.

**α-MSH enhances TG neuronal excitability through $I_A$ modulation**

$I_A$ encoded by Kv channels plays pivotal
roles in modulating membrane excitability in multiple excitable cell types including TG neurons (15,23). To determine the functional roles of the $I_A$ decrease mediated by MC4R activation, we investigated whether α-MSH application might affect the neuronal excitability. The application of 0.1 µM α-MSH to small-sized TG neurons had no effect on the whole-cell Nav currents (decrease of -2.7 ± 1.6 % at -10 mV, $n = 10$; Fig. 6A). It has been shown that the activation of MC4R inhibits presynaptic N-type Ca$^{2+}$ channels in amygdaloid complex neurons (35). To exclude the possible influence of α-MSH regulation of N-type as well as other types of Ca$^{2+}$ channels in TG neurons, we applied CdCl$_2$ (100 μM) in the external solution to block voltage-gated Ca$^{2+}$ channels during current-clamp recordings. We observed that the application of α-MSH at 0.1 µM significantly increased action potential (AP) firing frequency by 61.8 ± 5.3 % ($n = 15$; Figs. 6B and C). Additionally, 0.1 µM α-MSH significantly shortened first spike latency and increased AP amplitude ($n = 15$; Fig. 6D). Other membrane properties of neuronal excitability such as resting membrane potential and input resistance were not significantly changed by the α-MSH application (not shown). Pretreating TG neurons with the MC4R antagonist HS024 (0.5 µM) prevented the increased AP firing rate induced by 0.1 µM α-MSH, indicating the MC4R involvement ($n = 11$; Fig. 6E). To further verify that the MC4R-mediated neuronal hyperexcitability occurred through the decrease of $I_A$, we applied 4-AP in the external solution to block $I_A$ and found that application of 5 mM 4-AP mimicked the MC4R-mediated neuronal hyperexcitability ($n = 10$; Figs. 6F and G). Notably, application of α-MSH during the 4-AP-induced response failed to produce any further increase in firing frequency (Fig. 6G). These findings suggest that the MC4R-mediated $I_A$ decrease contributes to the α-MSH-induced TG neuronal hyperexcitability.

**α-MSH-mediated $I_A$ decrease induces pain hypersensitivity in vivo.**

To further determine the functional implications of MC4R at the behaviour level, we investigated whether α-MSH affects peripheral pain sensitivity in rats. The escape threshold to mechanical facial nociception was determined by an ascending series of von Frey filaments, which were applied to the buccal pad region. Intra-TG injection of α-MSH at 2 nmol induced a marked decrease in the escape threshold 1-2 h post-administration (Fig. 7A), and this effect recovered after 3 h. The α-MSH-mediated mechanical pain hypersensitivity was abrogated by intra-TG injection of the MC4R inhibitor HS024 at 5 nmol (Fig. 7B). The participation of $I_A$ in the α-MSH-mediated mechanical hypersensitivity was further examined using the specific A-type channel blocker 4-AP. Intra-TG application of 4-AP at 25 nmol exhibited a significant increase in mechanical sensitivity as compared with the control animals received saline injection (Fig. 7C). Sensitivity assessed after intra-TG injection of α-MSH showed that α-MSH had no additive effect to 4-AP on mechanical sensitivity in rats (Fig. 7C), which suggests that the effect of α-MSH and 4-AP can be mediated through the same signaling pathway in vivo. Collectively, our data provide evidence that the α-MSH-induced $I_A$ decrease contributes to the MC4R–mediated mechanical pain hypersensitivity in rats.

**Discussion**
This study reveals a novel functional role of \( \alpha \)-MSH in regulating \( I_A \) in rat TG neurons. We identify a signaling pathway that \( \alpha \)-MSH attenuates \( I_A \) through stimulation of the MC4R that coupled to a G\( \beta \gamma \) dependent class I PI3K and the downstream p38\( \alpha \) signaling (Figure 8). One of the immediate outcomes is the induction of sensory neuronal hyperexcitability and mechanical pain hypersensitivity.

Studies examining the PKA-dependent modulation of \( I_A \) lead to conflicting conclusions. In hippocampal pyramidal neurons, activation of PKA by 8-Br-cAMP significantly decreased \( I_A \) (36). Similarly, 3-isobutyl-1-methylxanthine stimulation of PKA down-regulated the peak current density of \( I_A \) (37). In contrast, PKA inducer mimicked the response of serotonin 1D receptor activator and was shown to stimulate \( I_A \) in TG neurons (38). In the current study, the decrease of \( I_A \) induced by \( \alpha \)-MSH was not affected by the PKA inhibitor PKI 6-22, suggesting that other mechanisms rather than PKA participated in the MC4R-mediated \( I_A \) response. We observed that in small-sized TG neurons the selective inhibition of \( I_A \) by MC4R activation was mediated by the class I PI3K and then relayed to the downstream p38-dependent signaling. Our data are consistent with previous studies conducted in early hippocampal neurons, which demonstrate that the PI3K/Akt signaling mediated the inhibition of \( I_A \) induced by Amyloid-\( \beta \) (39). Similarly, Kv currents including \( I_A \) recorded from pancreatic \( \beta \) cells decrease in response to PI3K activation (40). Interestingly, the activation of PI3K has been shown to increase \( I_A \) in cultured rat cerebellar granule cells (41), and PI3K-induced activation of Kv4.3 channel through glucocorticoid inducible kinase-1 has also been identified (42). Although the discrepancy requires further investigation, the regulatory effects of different PI3K subtypes including class I through class III might be variable in distinct tissue/cell types expressing Kv channels.

Akt is the most common component downstream of PI3K. Previous studies suggested that Akt may regulate the activity of Kv4 channels in a cell type- and signal-specific manner. For instance, in cultured cerebellar granule cells of rats, Akt has been shown to down-regulate Kv4.2 channels (43), while the Akt-dependent signaling stimulated Kv4 in the arcuate nucleus (44). In the present study, the MC4R-mediated \( I_A \) decrease appears not to be mediated by Akt in small TG neurons. Accumulating evidence has suggested the extracellular signal-regulated kinase-1 and -2 (ERK1/2) signaling involved in the modulation of pain (45). Additionally, ERK was shown to directly phosphorylate the pore-forming subunit of Kv4.2 channels (46), and activation of ERK attenuated \( I_A \) in neurons in superficial laminae of the spinal dorsal horn (34). In contrast, ERK signaling mediating the dopamine-induced \( I_A \) increase in lateral pyloric neurons was also reported (47). However, in this study, the stimulation of MC4R in small TG neurons resulted in the elevated level of p-p38 but not p-ERK or p-JNK, excluding the possible involvement of ERK in the MC4R-induced \( I_A \) response. Our findings are in line with previous studies conducted in dorsal root ganglion neurons and heart cells, in which the p38 activation led to decrease of Kv currents (48) by phosphorylation of the residues Y124 of Kv channels (49). On the contrary, p38 has been shown to stimulate Kv currents in transfected Chinese hamster ovary (CHO) cells (50). This discrepancy could be explained by distinct p38\( \alpha \) phosphorylation...
sites, or different Kv subtypes encoding $I_A$ in TG neurons and in modified CHO cells (51), or distinct splice variants of Kv channel-interacting protein (KCHIP) (52).

Changes of peripheral neuronal excitability can directly influence painful conditions such as hyperalgesia and allodynia in vivo (11-12). A-type channels, the key components influencing neuronal excitability, have been implicated in controlling both the delay of first-spike latency and the decrease in spike frequency (15,53), which are two important determinants in the release time course of neurotransmitter and hence the nociceptive transmission (54). An important consequence of peripheral A-type channel modulation is to influence somatic and visceral nociceptive inputs, and the decrease of $I_A$ results in significant nociception in a variety of animal neuropathic pain models (17). In the current study, consistent with the α-MSH–induced decrease in $I_A$ in small-sized TG neurons, activation of MC4R significantly increase TG neuronal excitability along with the shorter first-spike latency and increased firing frequency; blockade of $I_A$ by 4-AP prevented this effect. Moreover, the acute mechanical hypersensitivity induced by α-MSH was occluded by the A-type channel blocker application. As such, it is reasonable to infer that the nociceptive effects of MC4R activation are mediated, partially if not all, through its inhibition of $I_A$. Indeed, our present results are in line with previous in vivo studies that antagonism of MC4R reduced the chronic constriction injury (CCI)-induced allodynia in rodents (9,55-56), while activation of MC4R caused hyperalgesia in various pain models (6-8). Nevertheless, other potential channel targets other than A-type channels can also be activated by the MC4R pathway. It has been shown that the activation of MC4R with its agonist melanotan II inhibits presynaptic N-type Ca$^{2+}$ channels in amygdaloid complex neurons (35). In addition, MC4R constitutive activity inhibits Cav1.2 channel currents in transiently transfected HEK293 cells (57).

In summary, we present new insights underlying the effect of α-MSH on $I_A$ in small-sized TG neurons. Our findings indicated that α-MSH decreases $I_A$ through stimulation of a $G_{i/o}$-protein coupled MC4R and the downstream class I PI3K-mediated p38α signaling. The identified signaling pathway mediates the functional effects of α-MSH on induced sensory neuronal hyperexcitability and mechanical pain hypersensitivity. It would be interesting to further examine the effects of MC4R signaling on other types of pain (e.g. pain caused by thermal injuries) in the future work. Moreover, previous studies have revealed the expression of p38α was up-regulated in ipsilateral TGs in orofacial inflammatory pain model induced by complete Freund’s adjuvant (CFA) (58) and that pharmacological blockade of p38 activation reduced the CCI-induced thermal hyperalgesia (56). Therefore, the knowledge of MC4R-mediated p38α pathway in TG neurons in the present study may be applicable in other sensory neurons including DRG and may pave the way for MC4R to be developed as a potential therapeutic target for the clinical management of chronic pain.

**Experimental Procedures**

**Dissociation of TG neurons**

Rats were maintained in specific pathogen-free facilities on a 12:12 light/dark cycle at a room temperature (22 ± 1°C), and housed in cages with access to food and water ad libitum. All procedures in the
animal studies were approved by the Animal Studies Committee of Soochow University and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. TG neurons were dissociated from Sprague-Dawley rats (220 - 250 g, regardless of gender) according to the established protocol (38-39). Briefly, the TGs were dissected out bilaterally and the connective tissue was removed. After minced into 8-10 pieces, the tissues were enzymatically digested first with 1.5 mg/ml collagenase II (Worthington Biochemical) for 30 min, and then with 20 U/ml papain for 20 min (Worthington Biochemical). After papain treatment, the tissue was mechanically dissociated by trituration with sterile fire-polished glass pipettes. After centrifugation, the pellet was resuspended in minimum essential medium (MEM) (Invitrogen) containing 10% fetal bovine serum (FBS) (Hyclone, GE Healthcare Life Sciences), 2% B27 supplements (Invitrogen), 1% GlutaMAX, and 1% penicillin/streptomycin (Invitrogen), and then plated onto glass coverslips coated with matrigel. The cells were maintained at 37 °C in humidified incubators with 5% CO₂ and 95% air. Electrophysiological recordings were performed 2 - 6 hours after plating.

Whole-cell patch clamp recordings

Electrophysiological procedures were performed at room temperature (23 ± 1°C) as described previously (22,24). We chose only small-sized TG neurons that were less than 30 μm in soma diameter for patch clamp experiments. Pipettes (Sutter Instruments) had 3 - 5 MΩ resistance when filled with a pipette solution containing the following (in mM): 140 KCl, 10 HEPES, 1 MgCl₂, 0.5 CaCl₂, 5 EGTA, 0.5 Na₂GTP, and 3 Mg-ATP, with pH of 7.4 and osmolarity of 295 mosmol/kgH₂O. The recording chamber was superfused continuously with the external solution containing the following (in mM): 150 choline-Cl, 10 HEPES, 1 MgCl₂, 0.03 CaCl₂, 5 KCl, and 10 glucose, with pH of 7.4 and osmolarity of 310 mosmol/kgH₂O. Series resistance was compensated by at least 75% in voltage-clamp mode. Currents were filtered at 1 kHz and recorded using a MultiClamp 700B amplifier (Molecular Devices). The whole-cell current clamp was used to record changes in action potential firing of TG neurons. In whole-cell current clamp experiments and Nav current recordings, internal solution of electrodes contained (in mM) 10 NaCl, 110 KCl, 2 EGTA, 25 HEPES, 0.5 Na₂GTP, and 4 Mg-ATP, with pH of 7.3 and osmolarity of 295 mosmol/kgH₂O. The bath solution contained (in mM) 2 KCl, 128 NaCl, 2 CaCl₂, 2 MgCl₂, 30 glucose, and 25 HEPES, with pH of 7.4 and osmolarity of 305 mosmol/kgH₂O. During current clamp recordings, we applied 100 μM CdCl₂ in the external solution to block voltage-gated Ca²⁺ channels. In experiments in which neurons were dialyzed with compounds, patch pipettes resistance ranged from 2 to 3 MΩ for infusion; and currents were measured at least 5 min after breaking into the whole-cell configuration.

Detection of gene expression

Reverse transcription polymerase chain reaction (RT-PCR) was performed as described previously (30). Briefly, total RNA from rat entire TG tissues was extracted using an RNeasy Kit (Qiagen, Germantown, MD) according to the manufacturer’s protocol. RNA was treated with DNase (Promega Corp., Madison, WI) and then reverse transcribed with SuperScript™II (Thermo Fisher Scientific). The primers, designed in Primer 5.0 software (Premier Biosoft International, PA,
were derived from a partial genomic sequence: MC3R, accession number NM_001025270.3, forward 5'-TCTGCTG
TGCTGTGGGGGTG-3', reverse 5'-CGGT
TAGGCGGGTCGGGA T C-3'; MC4R, accession number NM_013099.3, forward
5'-CCAC AAGA GAAGCACCTAGA-3', reverse 5'-GTTG CCGTTCCTCACCACA G-3'. Experiments included non-reverse transcribed DNase-treated RNA samples as negative controls. PCR of these RT control groups never showed amplification, indicating that the RNA was genomic DNA free. The assays were carried out in duplicate using the same samples to confirm the reproducibility of the results. Western blot analysis

Western blot analyses were performed following the procedure as described previously (22,24). In brief, 25 μg extracted proteins were separated in 7.5% SDS-polyacrylamide gels and electroblotted onto polyvinylidine difluoride membranes (Merck Millipore). Membranes were blocked with 5% non-fat dry milk in TBST (0.05% Tween in Tris-buffered saline w/v) and were incubated overnight at 4 °C with primary antibodies. The following primary antibodies utilized included MC4R (rabbit, 1: 1000, Abcam), phospho-Akt (rabbit, 1: 1000, Cell Signaling Technology), Akt (rabbit, 1: 2000, Cell Signaling Technology), phospho-p38 (rabbit, 1: 600, Cell Signaling Technology), p38 (rabbit, 1: 1000, Cell Signaling Technology), p38α (rabbit, 1: 500, Santa Cruz Technology), p38β (rabbit, 1: 1000, Santa Cruz Technology), phospho-ERK1/2 (rabbit, 1: 1000, Cell Signaling Technology), ERK1/2 (rabbit, 1: 6000, Cell Signaling Technology), phospho-SAPK/JNK (rabbit, 1: 500, Cell Signaling Technology), SAPK/JNK (rabbit, 1: 1000, Cell Signaling Technology) and GAPDH (rabbit, 1: 3000, Abcam). After extensive washing, the membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and then reacted with enhanced chemiluminescence substrate (Pierce). Western blot signals were visualized using the ChemiDoc XRS System (Bio-Rad Laboratories). The Quantity One software (Bio-Rad Laboratories) was used for chemiluminescence measurements and quantification of the immunoblot data.

Immunofluorescence

The standard procedure of immunohistochemistry was performed as described in our previous studies (22). Briefly, after being sectioned (15 μm) in a cryostat (CM 1950; Leica), TG sections were blocked with 5% normal goat serum in phosphate buffer saline (PBS), plus 0.2% Triton X-100 for 1 hour and then incubated overnight in the primary antibody against MC4R (rabbit, 1: 500, Abcam), antibody against NF-200 (mouse, 1: 1000, Abcam), or antibody against CGRP (mouse, 1: 1000, Abcam). The sections were washed with PBS, followed by Cy3-conjugated goat anti-rabbit IgG (1: 500, Abcam), FITC-conjugated goat anti-mouse IgG (1: 400, Abcam) or IB 4-fluorescein isothiocyanate (5 μg/ml; Sigma-Aldrich) for 2 hours at room temperature. Slices were viewed under an upright fluorescence microscope (BX-51, Olympus) and images were taken using a CCD camera (DP70, Olympus). Negative controls incubated with secondary antibody only did not display any positive staining (not shown).

Measurement of PI3K activity

Phosphatidylinositol 3-kinase (PI3K) activity was determined as described previously (32). In brief, after stimulation of cells with α-MSH (0.1 μM) or Ro 27-3225 (0.2 μM) for 20 min, PI3K activity in
homogenates was determined using a PI3-Kinase HTRF™ Assay kit (Millipore Corporation, Bedford, MA) according to the manufacturer’s protocol. HTRF was then measured with an excitation wavelength of 335 nm and emission wavelengths of 620 and 665 nm with a spectrofluorometer (Tecan, Infinite M1000, Salzburg, Austria).

Adenovirus transduction
Adenovirus mediated gene silencing was performed following the procedure as described previously (22,32). Three candidate short hairpin RNAs (shRNAs) targeting p38α (GenBank accession number NM_031020.2) were designed, and best knockdown effects of shRNA sequence (5’-GGACCTCCTTA TAGACGAATG-3’) was selected. The nonsense sequence was designed as the negative control (NC-shRNA, 5’-ACCTGACTGTGTCAGGAAATCA-3’). The pAdTrack-CMV-GFP vector carrying p38α shRNA (p38α-shRNA) plasmid was packaged by Genechem Co., Ltd. (Shanghai, China). After 48 hours of infection, the efficiency of shRNA knockdown was determined by western blot analysis as described above. For electrophysiological analysis, small TG neurons expressing GFP were subjected to whole-cell recordings.

Escape threshold for mechanical stimulation
Animals (Sprague-Dawley rats, 220 - 250 g, regardless of gender) were housed under standard conditions (22 ± 1°C, 50% – 70% humidity, 12-12 hour light-dark cycle, with ad libitum access to food and water) and were allowed to habituate to laboratory conditions for at least 3 days prior to the experiments. The escape threshold to mechanical stimulation was determined by an ascending series of von Frey filaments (Ugo Basile) as described previously (59-60). Von Frey stimuli were applied to the buccal pad region and were applied three times in each series of trials. α-MSH (2 nmol), HS024 (5 nmol), or 4-AP (25 nmol) was intra-TG injected into the trigeminal ganglia with a 30 G needle inserted through the infraorbital foramen, infraorbital canal, and foramen rotundum. The needle tip was positioned in the medial part of the ganglia, and the treatment agent was slowly delivered in a volume of 5 μl.

Drugs application
CdCl2, 4-aminopyridine, cholera toxin, and pertussis toxin were purchased from Sigma-Aldrich (St. Louis, MO); α-MSH from Abcam; PKI 6-22 from Tocris Bioscience; Akt inhibitor III from Santa Cruz Biotechnology, all of which were prepared in distilled deionized water as stock solutions. Forskolin, wortmannin, Ro 27-3225, CH5132799 and SB203580 were obtained from Sigma-Aldrich (St. Louis, MO); HS024 from Tocris Bioscience; SB202474 from Merck Millipore; JX-401 from R&D systems, all of which were prepared as concentrated stock solutions in dimethylsulfoxide (DMSO). The final concentration of DMSO in the bath solution was less than 0.01%, and this compound had no functional effects on $I_A$ (not shown).

Data analysis
Data acquisition and analysis were done using Clampfit 10.2 software (Molecular Devices) and GraphPad Prism 5.0 (Prism Software). Data are expressed as original traces or presented as means ± S.E.M. The amplitude of $I_A$ was measured at the peak. The voltage dependence of activation and inactivation of $I_A$ was fitted with standard Boltzmann equations. A paired or two-sample $t$-test was used when comparisons were restricted to two means. Treatment effects were statistically analyzed using one-way analysis of variance (ANOVA) followed by Dunnett’s test or two-way ANOVA followed by Bonferroni’s
test. Error probabilities of $p < 0.05$ were considered statistically significant.

**Acknowledgments:** This study was supported by the National Natural Science Foundation of China (No. 81873731, No. 81771187, No. 81622014, No. 81671080, No. 81571063, No. 81371229), Innovation Project of Jiangsu Province (Qing-Lan Project to J. Tao), The Six Talent Peak Project of Jiangsu Province (No. JY-065), Jiangsu Key Laboratory of Neuropsychiatric Diseases (BM2013003), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

**Conflict of interest:** The authors declare that they have no conflicts of interest with the contents of this article.

**Author contributions:** ZQ, XJ and JT conceived the idea, planned the experiments, and wrote the manuscript. YZ, DJ, HL, and JT performed the experiments, wrote the manuscript and analyzed the data. YS contributed to designing experimental procedures. SG provided technical assistance. All authors reviewed the manuscript.

**References:**

1. Mountjoy, K. G., Caron, A., Hubbard, K., Shome, A., Grey, A. C., Sun, B., Bould, S., Middleditch, M., Pontre, B., McGregor, A., Harris, P. W. R., Kowalczyk, R., Brimble, M. A., Botha, R., Tan, K. M. L., Piper, S. J., Buchanan, C., Lee, S., Coll, A. P., and Elmquist, J. K. (2018) Desacetyl-alpha-melanocyte stimulating hormone and alpha-melanocyte stimulating hormone are required to regulate energy balance. *Mol Metab* 9, 207-216

2. Yang, Y., and Harmon, C. M. (2017) Molecular signatures of human melanocortin receptors for ligand binding and signaling. *Biochim Biophys Acta* 1863, 2436-2447

3. Adan, R. A., and Gispen, W. H. (1997) Brain melanocortin receptors: from cloning to function. *Peptides* 18, 1279-1287

4. Brzoska, T., Luger, T. A., Maaser, C., Abels, C., and Bohm, M. (2008) Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. *Endocr Rev* 29, 581-602

5. Bertolini, A., Tacchi, R., and Vergoni, A. V. (2009) Brain effects of melanocortins. *Pharmacol Res* 59, 13-47

6. Sandman, C. A., and Kastin, A. J. (1981) Intraventricular administration of MSH induces hyperalgesia in rats. *Peptides* 2, 231-233

7. Beltramo, M., Campanella, M., Tarozzo, G., Fredduzzi, S., Corradini, L., Forlani, A., Bertorelli, R., and Reggiani, A. (2003) Gene expression profiling of melanocortin system in neuropathic rats supports a role in nociception. *Brain Res Mol Brain Res* 118, 111-118

8. Klusa, V., Germane, S., Svirskis, S., Opmane, B., and Wikberg, J. E. (2001) The gamma(2)-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors. *Neuropeptides* 35, 50-57
9. Vrinten, D. H., Adan, R. A., Groen, G. J., and Gispen, W. H. (2001) Chronic blockade of melanocortin receptors alleviates allodynia in rats with neuropathic pain. *Anesth Analg* 93, 1572-1577, table of contents

10. Vrinten, D. H., Gispen, W. H., Groen, G. J., and Adan, R. A. (2000) Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. *J Neurosci* 20, 8131-8137

11. Julius, D., and Basbaum, A. I. (2001) Molecular mechanisms of nociception. *Nature* 413, 203-210

12. Waxman, S. G., and Zamponi, G. W. (2014) Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat Neurosci* 17, 153-163

13. Rasband, M. N., Park, E. W., Vanderah, T. W., Lai, J., Porreca, F., and Trimmer, J. S. (2001) Distinct potassium channels on pain-sensing neurons. *Proc Natl Acad Sci U S A* 98, 13373-13378

14. Luo, J. L., Qin, H. Y., Wong, C. K., Tsang, S. Y., Huang, Y., and Bian, Z. X. (2011) Enhanced excitability and down-regulated voltage-gated potassium channels in colonic drg neurons from neonatal maternal separation rats. *J Pain* 12, 600-609

15. Hu, H. J., Carrasquillo, Y., Karim, F., Jung, W. E., Nerbonne, J. M., Schwarz, T. L., and Gereau, R. W. t. (2006) The kv4.2 potassium channel subunit is required for pain plasticity. *Neuron* 50, 89-100

16. Takeda, M., Tsuboi, Y., Kitagawa, J., Nakagawa, K., Iwata, K., and Matsumoto, S. (2011) Potassium channels as a potential therapeutic target for trigeminal neuropathic and inflammatory pain. *Mol Pain* 7, 5

17. Duan, K. Z., Xu, Q., Zhang, X. M., Zhao, Z. Q., Mei, Y. A., and Zhang, Y. Q. (2012) Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model. *Pain* 153, 562-574

18. Chien, L. Y., Cheng, J. K., Chu, D., Cheng, C. F., and Tsaur, M. L. (2007) Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity. *J Neurosci* 27, 9855-9865

19. Chen, Y., Williams, S. H., McNulty, A. L., Hong, J. H., Lee, S. H., Rothflusz, N. E., Parekh, P. K., Moore, C., Gereau, R. W. t., Taylor, A. B., Wang, F., Guilak, F., and Liedtke, W. (2013) Temporomandibular joint pain: a critical role for Trpv4 in the trigeminal ganglion. *Pain* 154, 1295-1304

20. Tao, J., Liu, P., Xiao, Z., Zhao, H., Gerber, B. R., and Cao, Y. Q. (2012) Effects of familial hemiplegic migraine type 1 mutation T666M on voltage-gated calcium channel activities in trigeminal ganglion neurons. *J Neurophysiol* 107, 1666-1680

21. Orestes, P., Osuru, H. P., McIntire, W. E., Jacus, M. O., Salajegheh, R., Jagodic, M. M., Choe, W., Lee, J., Lee, S. S., Rose, K. E., Poiro, N., Digruccio, M. R., Krishnan, K., Covey, D. F., Lee, J. H., Barrett, P. Q., Jevtovic-Todorovic, V., and Todorovic, S. M. (2013) Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. *Diabetes* 62, 3828-3838

22. Zhang, Y., Ji, H., Wang, J., Sun, Y., Qian, Z., Jiang, X., Snutch, T. P., and Tao, J. (2018) Melatonin-mediated inhibition of Cav3.2 T-type Ca(2+) channels induces sensory neuronal hypoexcitability through the novel protein kinase C-eta isoform. *J Pineal Res* 64, e12476
23. Zhang, Y., Wang, H., Ke, J., Wei, Y., Ji, H., Qian, Z., Liu, L., and Tao, J. (2018) Inhibition of A-Type K+ Channels by Urotensin-II Induces Sensory Neuronal Hyperexcitability Through the PKCalpha-ERK Pathway. *Endocrinology* **159**, 2253-2263

24. Zhang, Y., Qin, W., Qian, Z., Liu, X., Wang, H., Gong, S., Sun, Y. G., Snutch, T. P., Jiang, X., and Tao, J. (2014) Peripheral pain is enhanced by insulin-like growth factor 1 through a G protein-mediated stimulation of T-type calcium channels. *Sci Signal* **7**, ra94

25. Winkelman, D. L., Beck, C. L., Ypey, D. L., and O'Leary, M. E. (2005) Inhibition of the A-type K+ channels of dorsal root ganglion neurons by the long-duration anesthetic butamben. *J Pharmacol Exp Ther* **314**, 1177-1186

26. van der Kraan, M., Tatro, J. B., Entwistle, M. L., Brakkee, J. H., Burbach, J. P., Adan, R. A., and Gispen, W. H. (1999) Expression of melanocortin receptors and pro-opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins. *Brain Res Mol Brain Res* **63**, 276-286

27. Tanabe, K., Gamo, K., Aoki, S., Wada, K., and Kiyama, H. (2007) Melanocortin receptor 4 is induced in nerve-injured motor and sensory neurons of mouse. *J Neurochem* **101**, 1145-1152

28. Adan, R. A., and Gispen, W. H. (2000) Melanocortins and the brain: from effects via receptors to drug targets. *Eur J Pharmacol* **405**, 13-24

29. Yue, J., Zhang, Y., Li, X., Gong, S., Tao, J., and Jiang, X. (2014) Activation of G-protein-coupled receptor 30 increases T-type calcium currents in trigeminal ganglion neurons via the cholera toxin-sensitive protein kinase A pathway. *Pharmazie* **69**, 804-808

30. Tao, J., Hildebrand, M. E., Liao, P., Liang, M. C., Tan, G., Li, S., Snutch, T. P., and Soong, T. W. (2008) Activation of corticotropin-releasing factor receptor 1 selectively inhibits CaV3.2 T-type calcium channels. *Mol Pharmacol* **73**, 1596-1609

31. Hu, C., Depuy, S. D., Yao, J., McIntire, W. E., and Barrett, P. Q. (2009) Protein kinase A activity controls the regulation of T-type CaV3.2 channels by Gbetagamma dimers. *J Biol Chem* **284**, 7465-7473

32. Zhang, Y., Ying, J., Jiang, D., Chang, Z., Li, H., Zhang, G., Gong, S., Jiang, X., and Tao, J. (2015) Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the betagamma subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C beta1 isoform. *J Biol Chem* **290**, 8644-8655

33. Ji, R. R., Gereau, R. W. t., Malcangio, M., and Strichartz, G. R. (2009) MAP kinase and pain. *Brain Res Rev* **60**, 135-148

34. Hu, H. J., Glauner, K. S., and Gereau, R. W. t. (2003) ERK integrates PKA and PKC signaling in superficial dorsal horn neurons. I. Modulation of A-type K+ currents. *J Neurophysiol* **90**, 1671-1679

35. Agosti, F., Lopez Soto, E. J., Cabral, A., Castrogiovanni, D., Schioth, H. B., Perello, M., and Raingo, J. (2014) Melanocortin 4 receptor activation inhibits presynaptic N-type calcium channels in amygdaloid complex neurons. *Eur J Neurosci* **40**, 2755-2765

36. Hoffman, D. A., and Johnston, D. (1998) Downregulation of transient K+ channels in
dendrites of hippocampal CA1 pyramidal neurons by activation of PKA and PKC. J Neurosci 18, 3521-3528
37. Coutts, C. A., Balt, L. N., and Ali, D. W. (2009) Protein kinase A modulates A-type potassium currents of larval zebrafish (Danio rerio) white muscle fibres. Acta Physiol (Oxf) 195, 259-272
38. Zhao, X., Zhang, Y., Qin, W., Cao, J., Ni, J., Sun, Y., Jiang, X., and Tao, J. (2016) Serotonin type-1D receptor stimulation of A-type K(+) channel decreases membrane excitability through the protein kinase A- and B-Raf-dependent p38 MAPK pathways in mouse trigeminal ganglion neurons. Cell Signal 28, 979-988
39. Wang, H., Qin, J., Gong, S., Feng, B., Zhang, Y., and Tao, J. (2014) Insulin-like growth factor-1 receptor-mediated inhibition of A-type K(+) current induces sensory neuronal hyperexcitability through the phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 pathways, independently of Akt. Endocrinology 155, 168-179
40. Xu, Y., Chiamvimonvat, N., Vazquez, A. E., Akumuru, S., Ratner, N., and Yamoah, E. N. (2002) Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism. J Neurosci 22, 9194-9202
41. Wu, R. L., Butler, D. M., and Barish, M. E. (1998) Potassium current development and its linkage to membrane expansion during growth of cultured embryonic mouse hippocampal neurons: sensitivity to inhibitors of phosphatidylinositol 3-kinase and other protein kinases. J Neurosci 18, 6261-6278
42. Lang, F., and Shumilina, E. (2013) Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J 27, 3-12
43. Pieri, M., Amadoro, G., Carunchio, I., Ciotti, M. T., Quaresima, S., Florenzano, F., Calissano, P., Possenti, R., Zona, C., and Severini, C. (2010) SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology 58, 268-276
44. Roepke, T. A., Malyala, A., Bosch, M. A., Kelly, M. J., and Ronneklev, O. K. (2007) Estrogen regulation of genes important for K+ channel signaling in the arcuate nucleus. Endocrinology 148, 4937-4951
45. Popiolek-Barczyk, K., Makuch, W., Rojewska, E., Pilot, D., and Mika, J. (2014) Inhibition of intracellular signaling pathways NF-kappaB and MEK1/2 attenuates neuropathic pain development and enhances morphine analgesia. Pharmacol Rep 66, 845-851
46. Schrader, L. A., Birnbaum, S. G., Nadin, B. M., Ren, Y., Bui, D., Anderson, A. E., and Sweatt, J. D. (2006) ERK/MAPK regulates the Kv4.2 potassium channel by direct phosphorylation of the pore-forming subunit. Am J Physiol Cell Physiol 290, C852-861
47. Rodgers, E. W., Krenz, W. D., Jiang, X., Li, L., and Baro, D. J. (2013) Dopaminergic tone regulates transient potassium current maximal conductance through a translational mechanism requiring D1Rs, cAMP/PKA, Erk and mTOR. BMC Neurosci 14, 143
48. Hagenacker, T., Hillebrand, I., Busselberg, D., and Schafers, M. (2010) Myricetin
reduces voltage activated potassium channel currents in DRG neurons by a p38 dependent mechanism. *Brain Res Bull* **83**, 292-296

49. Norris, C. A., He, K., Springer, M. G., Hartnett, K. A., Horn, J. P., and Aizenman, E. (2012) Regulation of neuronal proapoptotic potassium currents by the hepatitis C virus nonstructural protein 5A. *J Neurosci* **32**, 8865-8870

50. Redman, P. T., Hartnett, K. A., Aras, M. A., Levitan, E. S., and Aizenman, E. (2009) Regulation of apoptotic potassium currents by coordinated zinc-dependent signalling. *J Physiol* **587**, 4393-4404

51. Li, N., Lu, Z. Y., Yu, L. H., Burnstock, G., Deng, X. M., and Ma, B. (2014) Inhibition of G protein-coupled P2Y2 receptor induced analgesia in a rat model of trigeminal neuropathic pain. *Mol Pain* **10**, 21

52. Van Hoorick, D., Raes, A., Keysers, W., Mayeur, E., and Snyders, D. J. (2003) Differential modulation of Kv4 kinetics by KCHIP1 splice variants. *Mol Cell Neurosci* **24**, 357-366

53. Vydyanathan, A., Wu, Z. Z., Chen, S. R., and Pan, H. L. (2005) A-type voltage-gated K+ currents influence firing properties of isolectin B4-positive but not isolectin B4-negative primary sensory neurons. *J Neurophysiol* **93**, 3401-3409

54. Tolhurst, D. J., Smyth, D., and Thompson, I. D. (2009) The sparseness of neuronal responses in ferret primary visual cortex. *J Neurosci* **29**, 2355-2370

55. Starowicz, K., Mousa, S. A., Obara, I., Chocyk, A., Przewlocki, R., Wedzony, K., Machelska, H., and Przewlocka, B. (2009) Peripheral antinociceptive effects of MC4 receptor antagonists in a rat model of neuropathic pain - a biochemical and behavioral study. *Pharmacol Rep* **61**, 1086-1095

56. Chu, H., Xia, J., Yang, Z., and Gao, J. (2012) Melanocortin 4 receptor induces hyperalgesia and allodynia after chronic constriction injury by activation of p38 MAPK in DRG. *Int J Neurosci* **122**, 74-81

57. Agosti, F., Cordisco Gonzalez, S., Martinez Damonte, V., Tolosa, M. J., Di Siervi, N., Schioth, H. B., Davio, C., Perello, M., and Raingo, J. (2017) Melanocortin 4 receptor constitutive activity inhibits L-type voltage-gated calcium channels in neurons. *Neuroscience* **346**, 102-112

58. Dong, Y., Li, P., Ni, Y., Zhao, J., and Liu, Z. (2014) Decreased microRNA-125a-3p contributes to upregulation of p38 MAPK in rat trigeminal ganglia with orofacial inflammatory pain. *PLoS One* **9**, e111594

59. Zhang, Q., Cao, D. L., Zhang, Z. J., Jiang, B. C., and Gao, Y. J. (2016) Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice. *J Neuroinflammation* **13**, 183

60. Dixon, W. J. (1980) Efficient analysis of experimental observations. *Annu Rev Pharmacol Toxicol* **20**, 441-462

**The abbreviations used are:** α-MSH, alpha-melanocyte stimulating hormone; MC4R, melanocortin type 4 receptor; TG, trigeminal ganglion; Kv, voltage-gated K+ channels; IA, transient outward K’ channel currents; IDR, sustained delayed-rectifier K’ channel currents; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; MAPK, mitogen-activated protein kinase; CGRP, calcitonin gene related peptide; 4-AP, 4-aminopyridine.
FIGURE LEGENDS

**Fig. 1.** α-MSH decreases $I_A$ in TG neurons. A, representative current traces from small-sized TG neurons before (upper panel) and after (lower panel) application of 5 mM 4-aminopyridine (4-AP). Left: $I_A$ was isolated using a two-step voltage protocol. Right: $I_A$ was obtained after off-line subtraction of the noninactivating component. Insets in the top panel show the stimulation waveform, which was used for the $I_A$ isolation indicated in all figures. B, current-voltage (I/V) relationships of $I_A$ current density versus test potential for 5 mM 4-AP effects ($n = 9$). C-D, representative traces (C) and summary data of current density ($D$, $n = 8$) demonstrating that 0.1 µM α-MSH selectively decreases $I_A$. E, concentration-response curve plotting the inhibitory effects of α-MSH on $I_A$. The curves were fitted with a sigmoidal Hill function ($I/I_{control} = 1/(1 + 10^{(logEC50 - log[α-MSH])_{nH}})$ to compute the effective concentration at which the half-maximum effect occurs (EC$_{50}$). A number of cells tested at each concentration of α-MSH is shown in brackets. F-G, representative current traces (F) and I/V curves ($G$, $n = 8$) indicating the inhibitory effects of 0.1 µM α-MSH on the current density of $I_A$. The holding potential was -80 mV and currents are stimulated with voltage protocols from -70 to +70 mV with +10 mV increments. H-I, application of 0.1 μM α-MSH to TG neurons had no significant effect on the voltage dependence of activation potential ($H$, $n = 12$), but leftward shifted the half potential of the inactivation curve ($I$, $n = 12$). To measure the voltage dependence of activation, voltage stimuli lasting 400 ms were delivered with voltage steps ranging from -70 mV to +70 mV. To determine the steady-state inactivation, prepulses ranging from –120 to +20 mV were applied with 10 mV increments, followed by a 500 ms voltage step to +40 mV. J, bar graph showing the effects of 0.1 µM α-MSH on $V_{half}$ of the activation and inactivation curves. *$p < 0.05$ and **$p < 0.01$ versus control.

**Fig. 2.** The MC4R mediates the α-MSH-induced $I_A$ decrease. A, determination of MC3R and MC4R transcripts in rat TGs. The negative control without reverse transcriptase (-RT) did not show any signal. B, western blot analysis indicating the protein expression profile of MC4R (predicted band size 37 kDa). The GAPDH level served as a loading control. The blots shown are representative of three independent experiments. C, colocalization of MC4R (Red) with three markers (Green) (IB4, CGRP, and NF200) in naïve rat TG sections. Arrows show the colocalization. Scale bars: 40 µm. D, quantification of MCR4 colocalisation in TGs. E-F, time course of $I_A$ changes (E) and summary of results (F) showing that pre-incubation of neurons with HS024 (0.5 μM) prevented the 0.1 µM α-MSH-induced $I_A$ decrease. The alphabets on the plot indicate which points were utilized for sample traces. G-H, representative current traces (G) and summary of results of current density ($H$, $n = 6$) indicating the effect of 0.2 µM Ro 27-3225 on $I_A$. Insets show the representative current traces. *$p < 0.05$ versus control, ***$p < 0.001$ versus 0.1 µM α-MSH.

**Fig. 3.** The α-MSH-induced $I_A$ decrease requires the Gβγ-dependent PI3K. A-B, time course of changes in $I_A$ amplitude mediated by 0.1 µM α-MSH in CTX (0.5 µg/ml for 16 h pretreatment, $n = 10$, $A$) and PTX (0.2 µg/ml for 16 h pretreatment, $n = 8$, $B$), respectively. Insets show the representative current traces. The alphabets on the plot indicate which points were used for sample traces. C, summary data showing the effect of 0.1 µM α-MSH on $I_A$ in cells pretreated with CTX and PTX respectively indicated in panels $A$ and $B$. D, summary of results showing the effects of 0.1 µM α-MSH on $I_A$ in the presence of QEHA (10 µM, intracellular application,
n = 8), SKEE (10 µM, intracellular application, n = 11) and PKI 6-22 (1 µM, intracellular application, n = 9), respectively. E, representative current traces (left) and summary of results (right) depicting that dialysis with 1 µM PKI 6-22 prevented 20 µM forskolin-induced \(I_A\) response (n = 7). F, bar graph indicating that in cells pre-incubated with HS024 (0.5 µM) abolished the increase in PI3K activity induced by 0.1 µM α-MSH or 0.2 µM Ro 27-3225. All experiments were performed in triplicate with similar results. G, summary data indicating that treatment of TG cells with wortmannin (0.5 µM, n = 8) or CH5132799 (1 µM, n = 7) prevented the 0.1 µM α-MSH-induced \(I_A\) decrease. ***\(p < 0.001\) versus control, \#\(p < 0.05\) and \##\(p < 0.01\) versus vehicle, \@$p < 0.05\) versus α-MSH, \$\(p < 0.05\) versus Ro 27-3225.

**Fig. 4.** α-MSH attenuates \(I_A\) through activation of p38 MAPK. A, α-MSH at 0.1 µM induced a significant increase in the expression levels of phosphorylated Akt (p-Akt) in TG cells. This response was prevented by pretreatment with the Akt inhibitor III (Akt inhibitor, 10 µM). The blots shown are representative of three independent experiments. B, time course of \(I_A\) changes (left) and summary of results (right) showing that pre-incubation of cells with 10 µM Akt inhibitor did not affect the 0.1 µM α-MSH-induced \(I_A\) response (n = 11). The alphabets on the plot indicate which points were utilized for sample traces. Insets show the representative current traces. C, α-MSH at 0.1 µM significantly increased the protein expression levels of phosphorylated p38 (p-p38), but did not affect the levels of p-JNK and p-ERK in TG cells. All blots are representative of three independent experiments. D, pretreating TG cells with 0.5 µM wortmannin (wort.) abolished the 0.1 µM α-MSH-induced p38 activation. The blots shown are representative of three independent experiments. E-F, time course of changes in \(I_A\) amplitude mediated by 0.1 µM α-MSH in cells pretreated with 10 µM SB203580 (n = 9, E) or SB202474 (10 µM, n = 7, F). G, summary data showing that pretreating cells with 10 µM SB203580 prevented the 0.1 µM α-MSH-induced \(I_A\) decrease. *\(p < 0.05\), **\(p < 0.01\), and ***\(p < 0.001\) versus control.

**Fig. 5.** The p38α mediates the α-MSH-induced \(I_A\) response. A, western blot analysis showing that p38α, but not p38β, was endogenously expressed in rat TGs. Rat spinal cord was used as a positive control. The blots shown are representative of three independent experiments. B, time course of changes in \(I_A\) amplitude (left) and summary data (right) indicating the effect of α-MSH (0.1 µM) on \(I_A\) in cells pretreated with JX-401 (50 nM, n = 9). C, immunoblot analysis showed that the protein expression level of p38α was significantly reduced in p38α-shRNA transducing groups. Depicted immunoblots are representative of three different experiments. D, exemplary current traces (left) and summary data (right) demonstrating that the treatment of TG neurons with p38α-shRNA prevented the 0.1 µM α-MSH-induced decrease in \(I_A\) (n = 17). *\(p < 0.05\) and ***\(p < 0.001\) versus control, \#@\(p < 0.01\) versus NC-shRNA.

**Fig. 6.** α-MSH enhances TG neuronal excitability. A, I/V curves (left) and summary of results (right) depicting the effect of 0.1 µM α-MSH on the whole-cell Nav currents (\(I_{Na}\, n = 10\)). \(I_{Na}\) was elicited by a 40-ms depolarizing step pulse from -80 to +60 mV with the holding potential at -60 mV. B-C, exemplary traces of action potential (AP) firing (B) and summary of results (C) depicting the change of AP firing rate before vs. after 0.1 µM α-MSH application (n = 15). Current injections of +130 pA into the soma were shown in the top panels. D, bar graph showing that α-MSH at 0.1 µM significantly shortened first spike latency and increased the AP amplitude in small TG neurons (n = 15). E, summary of results depicting that
pretreating TG neurons with 0.5 μM HS024 abolished the increase of AP firing rate in response to 0.1 μM α-MSH (n = 11). F–G, representative traces of AP firing (F) and summary of results (G) depicting that pre-incubation of TG neurons with 5 mM 4-AP prevented the 0.1 μM α-MSH-induced neuronal hyperexcitability (n = 10). Current injections of +80 pA into the soma were shown in the top panels. *p < 0.05 and **p < 0.01 versus control.

**Fig. 7.** Involvement of peripheral MC4R in pain hypersensitivity. A, intra-TG injection of α-MSH (2 nmol), but not vehicle, induced a markedly mechanical pain hypersensitivity. *p < 0.05 and **p < 0.01, α-MSH versus vehicle, one-way ANOVA. BL, baseline. B, pretreatment of HS024 (5 nmol) prevented the α-MSH-induced mechanical hypersensitivity. *p < 0.05, α-MSH versus vehicle, *p < 0.05, α-MSH + HS024 versus α-MSH at 1 h, one-way ANOVA. Intra-TG injection of 5 nmol HS024 did not affect the basal escape threshold of normal rats. C, intra-TG pre-injection of 4-AP (25 nmol) occluded the mechanical hypersensitivity induced by 2 nmol α-MSH. *p < 0.05, α-MSH versus vehicle; **p < 0.01, 4-AP injection versus vehicle at 1 h. For all animal behavior data, N = at least 7 rats.

**Fig. 8.** The scheme of the proposed mechanisms of MC4R on \( I_A \). α-MSH acting through MC4R, which is coupled to the G-protein \( G_{i/o} \) causing it to release the \( G_{βγ} \) subunits. The released \( G_{βγ} \) caused an increase in class I PI3K activity in TG neurons. Stimulation of PI3K signaling may phosphorylate p38α to regulate \( I_A \) and induces TG neuronal hyperexcitability and pain hypersensitivity. PI3K can catalyse the conversion of phosphatidylinositol (4,5) bisphosphate (PIP2) to PIP3, which serves as a second messenger that helps to activate Akt. However, neither Akt nor PKA is necessary for the MC4R-mediated decrease of \( I_A \). Whether p38α in small-sized TG neurons directly phosphorylates \( I_A \) channel subtypes or acts through some intermediate signal molecules needs further investigation.
Figure 1

A) 400 ms pulse protocol with control and 4-AP 5 mM conditions.

B) Current-voltage relationship for control and α-MSH conditions with superimposed traces.

C) Graph showing decrease of IA (%).

D) Bar graph comparing IA and IaDR with control and α-MSH conditions.

E) Log [α-MSH] (M) graph with voltage (mV).

F) Control and α-MSH conditions with 200 ms pulse protocol.

G) Current-voltage relationship for control and α-MSH conditions.

H) Graph showing G/Gmax with control and α-MSH conditions.

I) Graph showing Vmax with control and α-MSH conditions.

J) Bar graph showing Vmax activation and inactivation with control and α-MSH conditions.
Figure 2

A. Gel electrophoresis showing bands for marker, TG, brain, and -RT. Bands for MC3R and MC4R are indicated.

B. Western blot showing bands for brain and TG. Bands for MC4R and GAPDH are indicated.

C. Confocal images showing MC4R, marker, and merged images. IB4, CGRP, and NF200 are indicated.

D. Bar graph showing percentage of MC4R-positive neurons. IB4, CGRP+, and NF200+ are indicated.

E. Graph showing current (I_A) over time (min) with +HS024 and α-MSH. Significant decreases are indicated.

F. Bar graph showing percentage decrease of I_A with HS024 and α-MSH. Significant decreases are indicated.

G. Graph showing current (I_A) over time (min) with Ro 27-3225. Significant decreases are indicated.

H. Bar graph showing current (I_A) over time (min) with control, Ro 27-3225, and washout. Significant differences are indicated.
Figure 3

A. Time course of \( I_A \) with \( \alpha \)-MSH in the presence of CTx.

B. Time course of \( I_A \) with \( \alpha \)-MSH in the presence of PTx.

C. Decrease of \( I_A \) by \( \alpha \)-MSH (%).

D. Decrease of \( I_A \) by \( \alpha \)-MSH (%).

E. Time course of \( I_A \) with forskolin in the presence of PKI 6-22.

F. PI3-Kinase activity (PIP3) (nM).

G. Decrease of \( I_A \) by forskolin (%).
Figure 4

**A**

![Western blot images showing phosphorylated Akt (p-Akt) and total Akt (t-Akt)]

**B**

![Graph showing decrease of I_A by α-MSH (%)]

**C**

![Western blot images showing phosphorylated ERK (p-ERK), total ERK (t-ERK), phosphorylated p38 (p-p38), total p38 (t-p38), and phosphorylated JNK (p-JNK)]

**D**

![Bar graph showing fold change of p-p38 / t-p38 under control and α-MSH conditions]

**E**

![Graph showing decrease of I_A by α-MSH (%)]

**F**

![Graph showing decrease of I_A by α-MSH (%)]

**G**

![Bar graph showing decrease of I_A by α-MSH (%)]
Figure 5

A

spinal cord
TG

40 kDa
35 kDa
40 kDa
35 kDa

p38α
GAPDH
p38β
GAPDH

B

+JX-401
α-MSH

I_A (nA)

Time (min)

 decrease of I_A by α-MSH (%)

C

40 kDa
35 kDa

p38α
GAPDH

NC-shRNA
p38α-shRNA

D

control
α-MSH 0.1 μM

Ad-NC-shRNA
Ad-PKCα-shRNA

current density (pA/pF)

Ad-NC-shRNA
p38α-shRNA

* ##
Figure 6

A. Voltage-dependent sodium current $I_{Na}$ (pA/pF) plotted against voltage (mV) for control and α-MSH-treated cells.

B. Trace comparison showing pre- and post-α-MSH effects on $I_{Na}$ with ±10 pA and ±20 pA current steps.

C. AP frequency (Hz) comparison between control and α-MSH-treated cells.

D. Summary of first spike latency (ms) and AP amplitude (mV) with statistical significance indicated by asterisks.

E. AP frequency (Hz) with HS024 application showing a significant difference between control and treated conditions.

F. AP frequency (Hz) with 4-AP application showing a significant difference between control and treated conditions.

G. AP frequency (Hz) with +4-AP showing a significant change in frequency.
Figure 7

A

\[ \text{vehicle} \quad \text{\( \alpha \)-MSH 2 nmol} \]

threshold (g)

BL 1 h 2 h 3 h

time

B

\[ \text{vehicle} \quad \text{\( \alpha \)-MSH 2 nmol} \]

threshold (g)

1 h +HS024

C

\[ \text{vehicle} \quad \text{\( \alpha \)-MSH 2 nmol} \]

threshold (g)

1 h +4-Ap
Figure 8

α-MSH (MC4R) activates Gβγ, which in turn activates PI3Kα. PI3Kα converts PIP2 to PIP3, which in turn activates PKA. PKA then activates p38α, ERK, JNK, and Akt. TG inhibits Akt activity, while (-) symbol indicates inhibition.
Melanocortin type 4 receptor–mediated inhibition of A-type K+ current enhances sensory neuronal excitability and mechanical pain sensitivity in rats
Yuan Zhang, Dongsheng Jiang, Hua Li, Yufang Sun, Xinghong Jiang, Shan Gong, Zhiyuan Qian and Jin Tao

J. Biol. Chem. published online February 11, 2019

Access the most updated version of this article at doi: 10.1074/jbc.RA118.006894

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts